Indaptus Therapeutics Inc - Asset Resilience Ratio
Indaptus Therapeutics Inc (INDP) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read INDP liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2023)
This chart shows how Indaptus Therapeutics Inc's Asset Resilience Ratio has changed over time. See net assets of Indaptus Therapeutics Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Indaptus Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see INDP company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Indaptus Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Indaptus Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Indaptus Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Indaptus Therapeutics Inc (2010–2023)
The table below shows the annual Asset Resilience Ratio data for Indaptus Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $14.92 Million | -- |
| 2022-12-31 | 59.88% | $16.81 Million | $28.06 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $40.58 Million | -- |
| 2019-12-31 | 3.62% | $770.00K | $21.28 Million | +1.45pp |
| 2018-12-31 | 2.17% | $1.33 Million | $61.51 Million | -0.66pp |
| 2017-12-31 | 2.83% | $1.82 Million | $64.55 Million | -4.66pp |
| 2016-12-31 | 7.49% | $1.85 Million | $24.72 Million | -11.40pp |
| 2015-12-31 | 18.90% | $7.04 Million | $37.28 Million | +2.81pp |
| 2014-12-31 | 16.08% | $2.01 Million | $12.49 Million | -21.59pp |
| 2013-12-31 | 37.67% | $5.15 Million | $13.68 Million | -1.86pp |
| 2012-12-31 | 39.53% | $3.07 Million | $7.77 Million | +22.72pp |
| 2011-12-31 | 16.81% | $1.52 Million | $9.06 Million | -23.81pp |
| 2010-12-31 | 40.62% | $5.09 Million | $12.54 Million | -- |
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency… Read more